Anterior ischaemic optic neuropathy: recurrent episodes in the same eye

ROY W. BECK,† PETER J. SAVINO,‡ NORMAN J. SCHATZ,‡ CRAIG H. SMITH,† AND ROBERT SERGOTT‡

From the †Neuro-Ophthalmology Unit, Wills Eye Hospital, and the ‡Departments of Neurology and Ophthalmology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

SUMMARY Anterior ischaemic optic neuropathy is characterised by a sudden, painless loss of vision, optic disc oedema, and nerve fibre bundle visual field defects. It may be associated with giant cell arteritis but is usually idiopathic. Although subsequent involvement of the second eye is common, more than one episode in the same eye is extremely rare. Four patients with recurrent anterior ischaemic optic neuropathy in the same eye are described.

Anterior ischaemic optic neuropathy (AION) is the result of infarction in the prelaminar portion of the optic nerve. It may be due to giant cell arteritis or may occur idiopathically. Visual loss is typically sudden and remains stable, without subsequent deterioration or improvement. Although involvement of the fellow eye is common, second ischaemic episodes in the same eye are extremely rare. We report here 4 cases of recurrent AION in the same eye (Table 1).

Case reports

CASE 1
A 61-year-old man reported the sudden onset of a cloud over the lower field of vision in his right eye. He had untreated chemical diabetes mellitus and mild hypertriglyceridaemia. Visual acuity was 6/12 OD and 6/6 OS. An afferent pupillary defect and an inferior altitudinal visual field defect were present in the right eye. The right optic disc had pallid swelling superiorly, with a telangiectatic pattern of fine vessels on its surface (Fig. 1a); the left disc and field were unremarkable. Intraocular tension, systemic blood pressure, and serum glucose were normal. Serum triglycerides were 275 mg/dl (3·1 mmol/l) (normal 50–175 (0·56–1·98 mmol/l)) and erythrocyte sedimentation rate (ESR) by the Westergren method was 13 mm/h. A diagnosis of nonarteritic ischaemic optic neuropathy was made. No treatment was instituted.

His vision remained unchanged for 3 weeks, when he experienced a second episode of sudden visual loss in his right eye, this time in the superior field. Acuity was 6/240 OD with only an island of visual field remaining in the superior nasal quadrant. The superior portion of the right disc was now pale, but most of the swelling had resolved, and dilated vessels were no longer present on its surface. The inferior portion of the disc, which had previously been normal, now had pallid oedema with haemorrhages in the adjacent nerve fibre layer (Fig. 1b). A repeat ESR was 10 mm/h. No therapy was instituted.

CASE 2
A 59-year-old man reported the sudden loss of vision in the inferior visual field of his right eye. He was otherwise well and his medical history was not remarkable. Visual acuity was 6/9 OD and 6/6 OS. An afferent pupillary defect and an inferior altitudinal visual field loss were found in the right eye. The right disc was pale and oedematous superiorly (Fig. 2a); the left disc and field were unremarkable. The intraocular tension, serum glucose, and ESR (21 mm/h) were normal. Systemic blood pressure was 190/110 mmHg. A diagnosis of nonarteritic ischaemic optic neuropathy was made. Antihypertensive treatment

*Dr Beck is currently with the Department of Ophthalmology, Neurology and Neurosurgery, University of Michigan School of Medicine, Ann Arbor, Michigan, and Dr Smith is with the Department of Neurology, University of Washington, Seattle, Washington.

Correspondence to Roy W. Beck, MD, Department of Ophthalmology, Scott Turner Building, 1010 Wall Street, Ann Arbor, Michigan 48109, USA.
Table 1  Clinical features of 4 patients with recurrent AION in the same eye

<table>
<thead>
<tr>
<th>Patient no./age/sex</th>
<th>Eye</th>
<th>Initial episode</th>
<th>Intervening period</th>
<th>Second episode</th>
<th>Medical conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Visual field</td>
<td>Disc</td>
<td>Visual field</td>
<td>Disc</td>
</tr>
<tr>
<td>1/61/M OD</td>
<td></td>
<td>Oedematous</td>
<td>3 weeks</td>
<td>Oedematous</td>
<td>Borderline AODM,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>superiorly</td>
<td></td>
<td>inferiorly</td>
<td>mild hypertriglyceridaemia</td>
</tr>
<tr>
<td>2/59/M OD</td>
<td></td>
<td>Oedematous</td>
<td>3 weeks</td>
<td>Oedematous</td>
<td>Hypertension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>superiorly</td>
<td></td>
<td>inferiorly</td>
<td></td>
</tr>
<tr>
<td>3/48/M OD</td>
<td></td>
<td>Oedematous</td>
<td>1 week</td>
<td>Oedematous</td>
<td>Mild hypertriglyceridaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>superiorly</td>
<td></td>
<td>inferiorly</td>
<td></td>
</tr>
<tr>
<td>4/52/M OS</td>
<td></td>
<td>Diffuse oedema</td>
<td>45 months</td>
<td>Diffuse oedema</td>
<td>Hypertension</td>
</tr>
</tbody>
</table>

was begun, but no specific therapy for the optic neuropathy was instituted.

Three weeks later the patient noted further sudden visual loss in his right eye. Visual acuity was reduced to hand movements with only an area of visual field in the superior nasal quadrant remaining. The right disc was now diffusely pale and oedematous, more so inferiorly, and new haemorrhage was present in the inferior peripapillary nerve fibre layer. Drusen were evident in the left optic disc, but the visual field in that eye was normal. Intraocular tension, serum glucose, systemic blood pressure, and ESR (18 mm/h) were normal. Serum triglycerides were 260 mg/dl (2-9 mmol/l (normal 50–175 (0-56–1-98 mmol/l)). A diagnosis of nonarteritic ischaemic optic neuropathy was made. No therapy was instituted.

One week later the patient experienced a second episode of sudden visual loss in the right eye. Visual acuity remained 6/7-5, but there was now a marked loss of the superior visual field. The previously normal inferior portion of the disc had pallid oedema and new linear haemorrhages. A repeat ESR was 16 mm/h. Cerebral arteriography and echocardiography were normal. He received no treatment.

Visual acuity was 6/7-5 OD and 6/6 OS. An afferent pupillary defect and a relative inferior altitudinal visual field defect were present in the right eye. The superior portion of the right optic disc had pallid oedema with haemorrhages in the adjacent nerve fibre layer. Drusen were evident in the left optic disc, but the visual field in that eye was normal. Intraocular tension, serum glucose, systemic blood pressure, and ESR (18 mm/h) were normal. Serum triglycerides were 260 mg/dl (2-9 mmol/l (normal 50–175 (0-56–1-98 mmol/l)). A diagnosis of nonarteritic ischaemic optic neuropathy was made. No therapy was instituted.

One week later the patient experienced a second episode of sudden visual loss in the right eye. Visual acuity remained 6/7-5, but there was now a marked loss of the superior visual field. The previously normal inferior portion of the disc had pallid oedema and new linear haemorrhages. A repeat ESR was 16 mm/h. Cerebral arteriography and echocardiography were normal. He received no treatment.

Case 3
A 48-year-old man reported the sudden onset of an area of blurring in the lower temporal quadrant of the right visual field. He was otherwise well and his medical history was not remarkable.
Anterior ischaemic optic neuropathy: recurrent episodes in the same eye

Case 1
(A) Right optic disc shows oedema superiorly with dilated vessels. The inferior portion of the disc appears normal. (B) Three weeks later the inferior portion of the disc is now oedematous with peripapillary haemorrhages. The superior portion of the disc is pale without oedema.

Three years later there was no significant change in visual function. The right disc became diffusely pale.

Case 4
A 52-year-old man reported the sudden onset of a 'blind spot' in his left eye. He was otherwise well and his medical history was unremarkable. Visual acuity was 6/6 OD and 6/7.5 OS with a left inferior arcuate defect demonstrable on perimetry. The left disc was diffusely oedematous, with linear haemorrhages in the adjacent nerve fibre layer. The right fundus and visual field were unremarkable. Intraocular tension, serum glucose, and ESR (20 mm/h) were normal. The systemic blood pressure was 150/95 mmHg. Cerebral arteriography gave normal results. He was
treated with 60 mg of prednisone daily by mouth, which was tapered over one month, but he had no improvement in vision.

Forty-five months later he experienced a second episode of sudden visual loss in the left eye. Visual acuity was reduced to 6/30 and perimetry showed further loss of the inferior visual field with involvement of fixation. The optic disc was again diffusely swollen, with haemorrhages at the disc margin. The ESR was 21 mm/h. He was treated with 60 mg of prednisone daily by mouth, tapered over one month, but his vision did not improve.

Fifteen months later he developed ischaemic optic neuropathy in his right eye. His left eye had not changed.

Discussion

The aetiology of AION, when it is not associated with giant cell arteritis, is presumed to be secondary to atherosclerotic changes in the optic disc vasculature, but pathological confirmation of this is lacking. About half the patients have hypertension, but the remainder lack any specific disease. Diabetes mellitus does not occur any more frequently than it does in the general population. Few patients have advanced systemic atherosclerotic disease, and there is good evidence that embolism is not a significant factor.

The clinical features of nonarteritic AION have been well described. It occurs mainly between the ages of 50 and 70. Visual acuity may be normal or decreased, depending upon whether the fibres of the papillomacular bundle are involved. Visual field defects are commonly of the nerve fibre bundle type, with altitudinal and arcuate defects being most typical. The inferior visual field is affected more frequently than the superior. The optic disc may be either partly or wholly oedematous, and, although it is typically pale, initially it may appear hyperaemic secondary to capillary dilatation. Streak haemorrhages at the disc margin are common. The visual deficit usually occurs suddenly and then remains stable, without subsequent deterioration or improvement. Oedema of the disc resolves within several weeks, leaving residual pallor, often in a sectoral or altitudinal fashion. No treatment has been found to be efficacious in controlled clinical studies.

Despite a 40% frequency of AION in the fellow eye, repeat attacks in the same eye are rare. Smith has stated that it never happens, but other authors have noted that it may occur. We have been able to find only 3 descriptions of patients with repeated episodes of AION in the same eye. In a retrospective analysis of 29 patients with idiopathic AION Boghen and Glaser reported on a 45-year-old woman who had a second episode of AION 2 years after the first. In a similar review of 48 patients with AION Ellenberger et al. described one patient who suffered a second episode of AION in each eye. Smith and Goldhammer reported on a 62-year-old hypertensive man with 2 episodes of visual loss in his left eye 3 years apart. The first produced a small superior temporal paracentral scotoma and the second an inferior nasal visual field defect. Fundoscopy 5 days after the second episode of visual loss showed slight dilatation of capillaries in the upper temporal portion of the disc. Fluorescein angiography demonstrated leakage in the same area.

A differentiation must be made between progression of a visual field deficit within a single episode of AION and a distinctly separate second episode. Boghen and Glaser found visual loss to be progressive to some degree in 11 out of 39 eyes. In most of the patients progression occurred over a period of one to 9 days. Ellenberger et al. had no patients in whom visual loss progressed over more than one day. Cullen found no evidence of progression in any of 19 patients with 'arteriosclerotic' AION. Miller and Smith described progression of visual loss in one of 11 patients with AION. This patient's visual acuity decreased from 6/9 at the initial examination to 6/21. The time course of the reduction in acuity and its aetiology were not discussed. Shults reported on a 39-year-old male who developed bilateral consecutive AION in whom visual loss progressed over about one week in each eye.

All 4 of our patients had a definite, documented second episode of AION. The interval between the 2 episodes in the first 3 cases was 3, 3, and 1 week respectively. Despite these relatively short intervals of time the 2 episodes in each patient were distinctly separate. In each case there was an initial sudden loss of inferior visual field which corresponded to an observed oedema of the superior portion of the disc. This field defect remained stable but was followed by a second apoplectic episode of visual loss involving the superior visual field. The inferior portion of the disc, which was initially normal, became oedematous with haemorrhages at the margin, while most of the oedema of the superior portion of the disc had resolved.

In patient 4 almost 4 years elapsed between the 2 episodes of AION. In both episodes there was diffuse disc oedema with haemorrhages in the adjacent nerve fibre layer and involvement of the inferior visual field. Our 4 patients differ in no way from the accepted clinical profile of AION. Their age range was 48 to 61 and all were in good health, without systemic evidence of significant atherosclerotic disease. The ESR was normal in each patient during each episode, and none had systemic symptoms or signs of giant cell arteritis.
Anterior ischaemic optic neuropathy: recurrent episodes in the same eye

arteritis. Two of the patients (2 and 4) had mild hypertension, one (3) had mild hypertriglyceridaemia, and one (1) had borderline untreated diabetes mellitus and mild hypertriglyceridaemia. In no patient was there evidence of any other systemic disease or embolic phenomena which may have contributed to optic nerve infarction. Two patients (3 and 4) were admitted to hospital and thoroughly examined for a systemic cause of repeated episodes of optic neuropathy, but none was found. Although there was no evidence of giant cell arteritis, two patients (2 and 4) received systemic corticosteroids, but neither had improvement in vision.

Why repeated episodes of AION in the same eye should occur so infrequently is not known. One possible explanation is that, having suffered one episode of AION, a patient might be less likely to recognise further visual loss in the same eye, and thus the calculated incidence of recurrent AION in the same eye might be falsely lowered. As evidence against this we detected additional asymptomatic visual field loss in only one of 58 patients with AION whom we have followed up with sequential perimetry for at least 3 years (unpublished data). It is more likely that certain unknown constant features of the structure of the optic nerve head or its blood supply provide the explanation. It is possible that when a portion of the optic disc is infarcted the blood supply which is subsequently shunted away from this area is sufficient to protect the remainder of the disc from a second ischaemic episode.

Two independent episodes of AION may occur in the same eye. Although rare, it does not appear to reflect any underlying systemic abnormality other than those noted in patients with AION in general.

This work was supported in part by a fellowship grant from the Heed Ophthalmic Foundation, Chicago (Dr Beck), and by a postdoctoral research fellowship from Fight For Sight, Inc., New York City (Dr Smith).

References

Anterior ischaemic optic neuropathy: recurrent episodes in the same eye.

R W Beck, P J Savino, N J Schatz, C H Smith and R Sergott

doi: 10.1136/bjo.67.10.705

Updated information and services can be found at:
http://bjo.bmj.com/content/67/10/705

**Email alerting service**

These include:
Receive free email alerts when new articles cite this article.
Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/